Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmed B Shamsulddin

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of the American College of Cardiology|November 26, 2025
Finerenone Withdrawal: More Rebound Than Relapse?Ahmed B Shamsulddin
JACC. Asia|June 3, 2026
Including Vonoprazan With PPIs Challenges the Drug-Interaction HypothesisAhmed B Shamsulddin
International Journal of Cardiology|June 24, 2025
Reframing the CHADS-P2A2RC score in chronic coronary syndrome: From ischemic risk stratification to a signal for cautionAhmed B Shamsulddin
Journal of Internal Medicine|August 4, 2025
Regarding: Systolic blood pressure targets below 120 mm Hg are associated with reduced mortality: A meta-analysisAhmed B Shamsulddin
JAMA Cardiology|March 25, 2026
Finerenone, New-Onset Atrial Fibrillation, and Prognosis in HFpEF/HFmrEFAhmed B Shamsulddin
Current Medical Research and Opinion|June 24, 2026
A novel hypothesis for stroke prediction, introducing CHA<sub>2</sub>DS<sub>2</sub>-VAScFAhmed B Shamsulddin
JACC. Heart Failure|January 7, 2026
Equally Effective in CASTLE-HTx: A Reassuring Signal, Not Definitive ProofAhmed B Shamsulddin
Cardiovascular Drugs and Therapy|May 13, 2025
Dissociation Between Mortality/Kidney Benefits and Neutral MACE Outcomes with ARNi in Heart Failure and Post-dialysis AKD RecoveryAhmed B Shamsulddin
The American Journal of Medicine|January 24, 2026
Preventing stroke or myocardial infarction?: The new monotherapy crossroads in atrial fibrillation and coronary artery diseaseAhmed B Shamsulddin
European Heart Journal. Quality of Care & Clinical Outcomes|August 12, 2025
The Semaglutide Paradox in Non-Overweight Diabetes: A Benefit Without ExplanationAhmed B Shamsulddin
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of the American College of Cardiology|November 26, 2025
Finerenone Withdrawal: More Rebound Than Relapse?Ahmed B Shamsulddin
JACC. Asia|June 3, 2026
Including Vonoprazan With PPIs Challenges the Drug-Interaction HypothesisAhmed B Shamsulddin
International Journal of Cardiology|June 24, 2025
Reframing the CHADS-P2A2RC score in chronic coronary syndrome: From ischemic risk stratification to a signal for cautionAhmed B Shamsulddin
Journal of Internal Medicine|August 4, 2025
Regarding: Systolic blood pressure targets below 120 mm Hg are associated with reduced mortality: A meta-analysisAhmed B Shamsulddin
JAMA Cardiology|March 25, 2026
Finerenone, New-Onset Atrial Fibrillation, and Prognosis in HFpEF/HFmrEFAhmed B Shamsulddin
Current Medical Research and Opinion|June 24, 2026
A novel hypothesis for stroke prediction, introducing CHA<sub>2</sub>DS<sub>2</sub>-VAScFAhmed B Shamsulddin
JACC. Heart Failure|January 7, 2026
Equally Effective in CASTLE-HTx: A Reassuring Signal, Not Definitive ProofAhmed B Shamsulddin
Cardiovascular Drugs and Therapy|May 13, 2025
Dissociation Between Mortality/Kidney Benefits and Neutral MACE Outcomes with ARNi in Heart Failure and Post-dialysis AKD RecoveryAhmed B Shamsulddin
The American Journal of Medicine|January 24, 2026
Preventing stroke or myocardial infarction?: The new monotherapy crossroads in atrial fibrillation and coronary artery diseaseAhmed B Shamsulddin
European Heart Journal. Quality of Care & Clinical Outcomes|August 12, 2025
The Semaglutide Paradox in Non-Overweight Diabetes: A Benefit Without ExplanationAhmed B Shamsulddin
Pageof 2